3月19日 - ** 精准肿瘤学公司黑钻石治疗公司（Black Diamond Therapeutics，BDTX.O）股价上涨35.1%，至2.26美元
** BDTX和法国制药商赛维（Servier） 表示，双方已 就BDTX-4933达成 许可协议，该小分子药物由黑钻公司设计
** BDTX将获得7000万美元的预付款，并有权获得高达7.1亿美元的研发和商业销售里程碑付款，以及基于全球净销售额的分级版税
** 根据协议，赛维将开发并商业化用于治疗包括非小细胞肺癌在内的 实体瘤的BDTX-4933
** BDTX-4933目前处于早期开发阶段
** 截至上次收盘，BDTX在过去12个月中下跌了64.2
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.